The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Allergan met expectations on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Gross margins expanded, operating margins dropped, net margins contracted.
Allergan recorded revenue of $1.41 billion. The 23 analysts polled by S&P Capital IQ anticipated sales of $1.43 billion on the same basis. GAAP reported sales were 6.4% higher than the prior-year quarter's $1.33 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.06. The 25 earnings estimates compiled by S&P Capital IQ anticipated $1.04 per share. GAAP EPS of $0.82 for Q3 were 1.2% higher than the prior-year quarter's $0.81 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 86.6%, 80 basis points better than the prior-year quarter. Operating margin was 25.3%, 100 basis points worse than the prior-year quarter. Net margin was 17.6%, 120 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.51 billion. On the bottom line, the average EPS estimate is $1.20.
Next year's average estimate for revenue is $5.82 billion. The average EPS estimate is $4.17.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 414 members out of 436 rating the stock outperform, and 22 members rating it underperform. Among 120 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 117 give Allergan a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $100.98.
- Add Allergan to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.